Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab in head and neck squamous cell carcinoma
ISRCTN98745687Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of amivantamab in head and neck squamous cell carcinoma (HNSCC) (7 cohorts), sponsored by Janssen Pharmaceutical. Started Apr 2024; status: recruiting.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN98745687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN98745687.